https://www.selleckchem.com/pr....oducts/tuvusertib.ht
ng has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid establishment of COVID-19 clinical trials and
Curtir
Comentario
Compartilhar
